PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.31
-0.01 (-3.12%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.32
Open0.32
Bid0.00 x 800
Ask0.35 x 1800
Day's Range0.29 - 0.33
52 Week Range0.29 - 2.15
Volume1,175,548
Avg. Volume647,613
Market Cap7.178M
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateNov 15, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted in Media

    The scientific and economic advantages of the proprietary, ultra-sensitive ICE-COLD PCR (ICP) technology developed by specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) were recently spotlighted in several industry media outlets. A Drug Delivery Business News article titled “Tracking tumors with Precipio’s liquid biopsy tech” discusses the role liquid biopsies can play in cancer treatment and why the economics of monitoring is important. A Clinical Lab Products article titled “Inside Track: In the Trenches” provides a Q&A with Precipio CEO Ilan Danieli.

  • GlobeNewswire7 days ago

    Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced preliminary third quarter results representing continued triple digit percentage year-over-year quarterly revenue growth. Pathology services, Precipio’s core business, showed quarter over quarter sequential growth of approximately 20%. Management will review the drivers of pathology services in its upcoming shareholder conference call following the SEC filing of Precipio’s third quarter 2018 results.

  • GlobeNewswire20 days ago

    Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the commercial launch of HemeScreen, a novel proprietary test for mutations in hematologic cancers. Precipio is the first to offer a low cost, rapid molecular screening panel for hematologic mutations. Reagents: A set of RUO reagents sold to other reference labs to perform the test in their CLIA laboratories.

  • GlobeNewswire26 days ago

    Precipio Granted 180 Day NASDAQ Extension to Regain Compliance

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Market Exchange. “These additional six months provide more time for our operational, commercial and strategic initiatives to materialize, and for management to build the value of the company,” commented Ilan Danieli, Precipio’s CEO.

  • GlobeNewswirelast month

    Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M

    Specialty cancer diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces the restructuring of its remaining legacy, pre-merger accounts payable liabilities, pursuant to an exchange which is made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933. The payments made to note holders are equal to approximately 20% of the original $5.3 million, and are funded through a convertible note with existing investors. Important benefits of this transaction include the postponement of $82,000 in monthly debt service for a period of 12 months, and the ability during that time to convert the notes at a 65% premium to market, effectively reducing by almost half the dilution that would have otherwise resulted from raising capital necessary to satisfy these obligations.

  • GlobeNewswirelast month

    Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering

    The kit provides physicians the ability to use a liquid biopsy to identify patients eligible for Tyrosine Kinase Inhibitor (TKI) therapies through analysis of tumor DNA for these critical EGFR mutations. The presence of such mutations indicates the patient’s eligibility for various targeted therapies including TKI. This kit complements Precipio’s previously-launched TKI-resistance detection kit, providing the clinician with a full suite of sequential lung-cancer diagnostic tools critical to determining patient treatment.

  • ACCESSWIRE2 months ago

    Precipio, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 23, 2018 at 9:00 AM Eastern Time. To ...

  • GlobeNewswire2 months ago

    Precipio Reminds Investors of Conference Call with Management for Corporate Update and Second Quarter Results

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and shareholders of its previously announced shareholder conference call scheduled for tomorrow, Thursday August 23, 2018 at 9:00 am EDT, where management will provide a strategic business update and address questions submitted in advance via email. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

  • GlobeNewswire2 months ago

    Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has filed its form 10-Q and released it’s financial results for the second quarter ended June 30, 2018. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

  • GlobeNewswire2 months ago

    Precipio Appoints New Board Member to Replace Departing Director

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the appointment of veteran life sciences venture capitalist and executive Kathleen LaPorte to its board of directors as an independent member. Ms. LaPorte will replace Dr. Michael Allen Luther who served on Transgenomic’s board since 2014 and remained as member of Precipio’s board since the merger in June 2017.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Texas Instruments and Precipio

    NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Texas Instruments Incorporated closed down modestly on Wednesday. The company's CEO Brian Crutcher recently resigned for violating conduct and in his place, former CEO Rich Templeton has taken his position. Shares of Precipio saw big gains after announcing preliminary second quarter results.

  • ACCESSWIRE4 months ago

    Initiating Free Research Reports on Quest Diagnostics and Three Other Medical Research Equities

    Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...

  • Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?
    Simply Wall St.5 months ago

    Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?

    In this analysis, my focus will be on developing a perspective on Precipio Inc’s (NASDAQ:PRPO) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • ACCESSWIRE5 months ago

    Complimentary Technical Snapshots on Thermo Fisher Scientific and Three More Medical Research Stocks

    Ahead of today's trading session, WallStEquities.com scans four Medical Laboratories and Research stocks, particularly: PerkinElmer Inc. (NYSE: PKI), Precipio Inc. (NASDAQ: PRPO), Syneos Health Inc. (NASDAQ: SYNH), and Thermo Fisher Scientific Inc. (NYSE: TMO). Medical laboratories are independent, commercial enterprises that provide information to the health care professionals about the severity, onset, and reason of patients' physical ailments.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Precipio and Teva Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Shares of Precipio and Teva were gaining full speed on Monday. Precipio shares exploded after the company announced a substantial preliminary unaudited first ...